{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:57:32Z","timestamp":1786982252511,"version":"build-2736575974"},"reference-count":228,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04185-5","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T11:02:10Z","timestamp":1767524530000},"page":"2014-2040","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology"],"prefix":"10.1007","volume":"28","author":[{"given":"Jinxin","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis Andreevich","family":"Nikolenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxrat","family":"Boymuradov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilya","family":"Garifulina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5908-6078","authenticated-orcid":false,"given":"Elnaz","family":"Khodabandehloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"key":"4185_CR1","unstructured":"AUCATZYL: The FDA; 2024 [Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/aucatzyl."},{"issue":"5","key":"4185_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"issue":"1","key":"4185_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980.","journal-title":"N Engl J Med"},{"issue":"26","key":"4185_CR4","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"key":"4185_CR5","unstructured":"FDA approves brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukemia: the FDA; 2021 [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic."},{"key":"4185_CR6","unstructured":"FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma: the FDA; 2021 [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-large-b-cell-lymphoma."},{"issue":"8","key":"4185_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"issue":"3","key":"4185_CR8","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/s2352-3026(24)00005-x","volume":"11","author":"M Delforge","year":"2024","unstructured":"Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, et al. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024;11(3):e216\u201327. https:\/\/doi.org\/10.1016\/s2352-3026(24)00005-x.","journal-title":"Lancet Haematol"},{"issue":"10297","key":"4185_CR9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/s0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(21)00933-8.","journal-title":"Lancet"},{"issue":"2","key":"4185_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","volume":"29","author":"V Ort\u00edz-Maldonado","year":"2021","unstructured":"Ort\u00edz-Maldonado V, Rives S, Castell\u00e0 M, Alonso-Saladrigues A, Ben\u00edtez-Ribas D, Caballero-Ba\u00f1os M, et al. CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19(+) relapsed\/refractory malignancies. Mol Ther. 2021;29(2):636\u201344. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.027.","journal-title":"Mol Ther"},{"key":"4185_CR11","unstructured":"Therapeutics J. JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma: JW Therapeutics; 2021 [Available from: https:\/\/www.jwtherapeutics.com\/en\/media\/press-release\/jw-therapeutics-announces-nmpa-approval-of-relmacabtagene-autoleucel-injection-in-patients-with-relapsed-or-refractory-follicular-lymphoma\/."},{"key":"4185_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008857","author":"W Liu","year":"2024","unstructured":"Liu W, Zou H, Chen L, Huang W, Lv R, Xu Y, et al. Combinational therapy of CAR T-cell and HDT\/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed\/refractory large B-cell lymphoma. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-008857.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"4185_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40291-023-00673-y","volume":"27","author":"SJ Keam","year":"2023","unstructured":"Keam SJ. Equecabtagene autoleucel: first approval. Mol Diagn Ther. 2023;27(6):781\u20137. https:\/\/doi.org\/10.1007\/s40291-023-00673-y.","journal-title":"Mol Diagn Ther"},{"issue":"Supplement 1","key":"4185_CR14","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1182\/blood-2022-168610","volume":"140","author":"W Chen","year":"2022","unstructured":"Chen W, Fu C, Fang B, Liang A, Xia Z, He Y, et al. Phase \u2161 study of fully human BCMA-targeting CAR-T cells (zevorcabtagene autoleucel) in patients with relapsed\/refractory multiple myeloma. Blood. 2022;140(Supplement 1):4564\u20135. https:\/\/doi.org\/10.1182\/blood-2022-168610.","journal-title":"Blood"},{"issue":"S1","key":"4185_CR15","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1182\/blood-2023-184373","volume":"142","author":"C Fu","year":"2023","unstructured":"Fu C, Chen W, Cai Z, Yan L, Wang H, Shang J, et al. Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma. Blood. 2023;142(S1):4845.","journal-title":"Blood"},{"key":"4185_CR16","doi-asserted-by":"publisher","first-page":"1045024","DOI":"10.3389\/fimmu.2023.1045024","volume":"14","author":"K Zhang","year":"2023","unstructured":"Zhang K, Chen H, Li F, Huang S, Chen F, Li Y. Bright future or blind alley? CAR-T cell therapy for solid tumors. Front Immunol. 2023;14:1045024. https:\/\/doi.org\/10.3389\/fimmu.2023.1045024.","journal-title":"Front Immunol"},{"key":"4185_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1448709","author":"Y Ma","year":"2024","unstructured":"Ma Y, Zhou H, Zhang J, Zhang Q, Li Y, Xie R, et al. The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1448709.","journal-title":"Front Immunol"},{"issue":"1","key":"4185_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20(1):49\u201362. https:\/\/doi.org\/10.1038\/s41571-022-00704-3.","journal-title":"Nat Rev Clin Oncol"},{"issue":"22","key":"4185_CR19","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton MP, Sugio T, Noordenbos T, Shi S, Bulterys PL, Liu CL, et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N Engl J Med. 2024;390(22):2047\u201360. https:\/\/doi.org\/10.1056\/NEJMoa2401361.","journal-title":"N Engl J Med"},{"key":"4185_CR20","doi-asserted-by":"publisher","first-page":"1398078","DOI":"10.3389\/fonc.2024.1398078","volume":"14","author":"S Arya","year":"2024","unstructured":"Arya S, Shahid Z. Overview of infectious complications among CAR T- cell therapy recipients. Front Oncol. 2024;14:1398078. https:\/\/doi.org\/10.3389\/fonc.2024.1398078.","journal-title":"Front Oncol"},{"key":"4185_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115888","volume":"169","author":"V Moradi","year":"2023","unstructured":"Moradi V, Omidkhoda A, Ahmadbeigi N. The paths and challenges of \u201coff-the-shelf\u201d CAR-T cell therapy: an overview of clinical trials. Biomed Pharmacother. 2023;169:115888. https:\/\/doi.org\/10.1016\/j.biopha.2023.115888.","journal-title":"Biomed Pharmacother"},{"key":"4185_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1388475","author":"V Moradi","year":"2024","unstructured":"Moradi V, Khodabandehloo E, Alidadi M, Omidkhoda A, Ahmadbeigi N. Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review. Front Oncol. 2024. https:\/\/doi.org\/10.3389\/fonc.2024.1388475.","journal-title":"Front Oncol"},{"issue":"9","key":"4185_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12032-025-02928-6","volume":"42","author":"YA Albalawi","year":"2025","unstructured":"Albalawi YA. Applications of nanoparticles in CAR-T cell therapy: non-viral manufacturing, enhancing in vivo function, and in vivo generation of CAR-T cells. Med Oncol. 2025;42(9):378. https:\/\/doi.org\/10.1007\/s12032-025-02928-6.","journal-title":"Med Oncol"},{"key":"4185_CR24","doi-asserted-by":"publisher","first-page":"S306","DOI":"10.1016\/j.htct.2024.05.005","volume":"46","author":"A dos Rodrigues Santos","year":"2024","unstructured":"dos Rodrigues Santos A, Zanini D, Andolfatto D. Cytokine release syndrome after chimeric antigen receptor T cell therapy in patients with diffuse large B-cell lymphoma: a systematic review. Hematol Transfus Cell Ther. 2024;46:S306\u201315. https:\/\/doi.org\/10.1016\/j.htct.2024.05.005.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"21","key":"4185_CR25","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295\u2013306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141.","journal-title":"Blood"},{"issue":"4","key":"4185_CR26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jcyt.2020.01.015","volume":"22","author":"JX Cao","year":"2020","unstructured":"Cao JX, Wang H, Gao WJ, You J, Wu LH, Wang ZX. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. Cytotherapy. 2020;22(4):214\u201326. https:\/\/doi.org\/10.1016\/j.jcyt.2020.01.015.","journal-title":"Cytotherapy"},{"issue":"16","key":"4185_CR27","doi-asserted-by":"publisher","first-page":"7528","DOI":"10.1200\/JCO.2023.41.16_suppl.7528","volume":"41","author":"MJ Frigault","year":"2023","unstructured":"Frigault MJ, Amoloja T, Burke LM, Morariu-Zamfir R, Bhatt V, Bibeau K, et al. Rates of cytokine release syndrome (CRS) and immune effector cell\u2013associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T). J Clin Oncol. 2023;41(16):7528.","journal-title":"J Clin Oncol"},{"key":"4185_CR28","volume-title":"Stem Cell Transplantation","author":"N Thalambedu","year":"2025","unstructured":"Thalambedu N, Vellanki S, Trikannad AK, Varma A. CART Cell Toxicities and Management. In: Piccaluga PP, Visani G, Khattab SS, editors. Stem Cell Transplantation. Rijeka: IntechOpen; 2025."},{"key":"4185_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950923","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Ming Y, Fu R, Li C, Wu Y, Jiang T, et al. The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Front Pharmacol. 2022;13:950923. https:\/\/doi.org\/10.3389\/fphar.2022.950923.","journal-title":"Front Pharmacol"},{"key":"4185_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01973","volume":"11","author":"EL Siegler","year":"2020","unstructured":"Siegler EL, Kenderian SS. Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies. Front Immunol. 2020;11:1973. https:\/\/doi.org\/10.3389\/fimmu.2020.01973.","journal-title":"Front Immunol"},{"key":"4185_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1530623","author":"Q Zhou","year":"2025","unstructured":"Zhou Q, An Y, Zhang X, Xiao X, Bai X, Liu P, et al. Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1530623.","journal-title":"Front Immunol"},{"issue":"1","key":"4185_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, M\u00fcller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34\u201348. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.478.","journal-title":"Ann Oncol"},{"issue":"4","key":"4185_CR33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jtct.2025.01.884","volume":"31","author":"L Maillie","year":"2025","unstructured":"Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, et al. Prolonged neurologic symptoms following immune effector cell-associated neurotoxicity syndrome in patients with large B-cell lymphoma treated with chimeric antigen receptor-modified T cell therapy. Transplant Cell Ther. 2025;31(4):228\u201335. https:\/\/doi.org\/10.1016\/j.jtct.2025.01.884.","journal-title":"Transplant Cell Ther"},{"key":"4185_CR34","doi-asserted-by":"publisher","first-page":"1144414","DOI":"10.3389\/fneur.2023.1144414","volume":"14","author":"R Velasco","year":"2023","unstructured":"Velasco R, Mussetti A, Villagr\u00e1n-Garc\u00eda M, Sureda A. CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: is it still a concern? Front Neurol. 2023;14:1144414. https:\/\/doi.org\/10.3389\/fneur.2023.1144414.","journal-title":"Front Neurol"},{"key":"4185_CR35","doi-asserted-by":"publisher","first-page":"1392831","DOI":"10.3389\/fneur.2024.1392831","volume":"15","author":"MW Han","year":"2024","unstructured":"Han MW, Jeong SY, Suh CH, Park H, Guenette JP, Huang RY, et al. Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis. Front Neurol. 2024;15:1392831. https:\/\/doi.org\/10.3389\/fneur.2024.1392831.","journal-title":"Front Neurol"},{"issue":"23","key":"4185_CR36","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1182\/blood.2020008865","volume":"137","author":"P Strati","year":"2021","unstructured":"Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021;137(23):3272\u20136. https:\/\/doi.org\/10.1182\/blood.2020008865.","journal-title":"Blood"},{"key":"4185_CR37","unstructured":"Justiz Vaillant AA, Modi P, Mohammadi O. Graft-Versus-Host Disease. StatPearls. Treasure Island (FL) with ineligible companies. Disclosure: Pranav Modi declares no relevant financial relationships with ineligible companies. Disclosure: Oranus Mohammadi declares no relevant financial relationships with ineligible companies.: StatPearls Publishing. Copyright \u00a9 2025, StatPearls Publishing LLC.; 2025."},{"key":"4185_CR38","doi-asserted-by":"publisher","first-page":"1388475","DOI":"10.3389\/fonc.2024.1388475","volume":"14","author":"V Moradi","year":"2024","unstructured":"Moradi V, Khodabandehloo E, Alidadi M, Omidkhoda A, Ahmadbeigi N. Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review. Front Oncol. 2024;14:1388475. https:\/\/doi.org\/10.3389\/fonc.2024.1388475.","journal-title":"Front Oncol"},{"issue":"3","key":"4185_CR39","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jcyt.2024.11.013","volume":"27","author":"R Traynor","year":"2025","unstructured":"Traynor R, Vignola I, Sarkar S, Prochazkova M, Cai Y, Shi R, et al. Efficient manufacturing of CAR-T cells from whole blood: a scalable approach to reduce costs and enhance accessibility in cancer therapy. Cytotherapy. 2025;27(3):400\u20139. https:\/\/doi.org\/10.1016\/j.jcyt.2024.11.013.","journal-title":"Cytotherapy"},{"issue":"7","key":"4185_CR40","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. N Engl J Med. 2024;390(7):584\u20136. https:\/\/doi.org\/10.1056\/NEJMp2400209.","journal-title":"N Engl J Med"},{"issue":"20","key":"4185_CR41","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.Ccr-24-1798","volume":"30","author":"T Tix","year":"2024","unstructured":"Tix T, Alhomoud M, Shouval R, Cliff ERS, Perales MA, Cordas Dos Santos DM, et al. Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients. Clin Cancer Res. 2024;30(20):4690\u2013700. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-1798.","journal-title":"Clin Cancer Res"},{"key":"4185_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122683","volume":"348","author":"Y Metanat","year":"2024","unstructured":"Metanat Y, Viktor P, Amajd A, Kaur I, Hamed AM, Abed Al-Abadi NK, et al. The paths toward non-viral CAR-T cell manufacturing: a comprehensive review of state-of-the-art methods. Life Sci. 2024;348:122683. https:\/\/doi.org\/10.1016\/j.lfs.2024.122683.","journal-title":"Life Sci"},{"issue":"7709","key":"4185_CR43","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558(7709):307\u201312. https:\/\/doi.org\/10.1038\/s41586-018-0178-z.","journal-title":"Nature"},{"issue":"15","key":"4185_CR44","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","volume":"3","author":"NN Shah","year":"2019","unstructured":"Shah NN, Qin H, Yates B, Su L, Shalabi H, Raffeld M, et al. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Adv. 2019;3(15):2317\u201322. https:\/\/doi.org\/10.1182\/bloodadvances.2019000219.","journal-title":"Blood Adv"},{"issue":"6","key":"4185_CR45","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMoa2411507","volume":"392","author":"K Perica","year":"2025","unstructured":"Perica K, Jain N, Scordo M, Patel R, Eren OC, Patel U, et al. CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N Engl J Med. 2025;392(6):577\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2411507.","journal-title":"N Engl J Med"},{"issue":"16","key":"4185_CR46","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood.2021010858","volume":"138","author":"KP Micklethwaite","year":"2021","unstructured":"Micklethwaite KP, Gowrishankar K, Gloss BS, Li Z, Street JA, Moezzi L, et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood. 2021;138(16):1391\u2013405. https:\/\/doi.org\/10.1182\/blood.2021010858.","journal-title":"Blood"},{"issue":"10","key":"4185_CR47","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","volume":"57","author":"K Wudhikarn","year":"2022","unstructured":"Wudhikarn K, Perales MA. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2022;57(10):1477\u201388. https:\/\/doi.org\/10.1038\/s41409-022-01756-w.","journal-title":"Bone Marrow Transplant"},{"key":"4185_CR48","doi-asserted-by":"publisher","DOI":"10.1177\/20499361211036773","volume":"8","author":"AG Stewart","year":"2021","unstructured":"Stewart AG, Henden AS. Infectious complications of CAR T-cell therapy: a clinical update. Ther Adv Infect Dis. 2021;8:20499361211036773. https:\/\/doi.org\/10.1177\/20499361211036773.","journal-title":"Ther Adv Infect Dis"},{"key":"4185_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26914","author":"A Doan","year":"2018","unstructured":"Doan A, Pulsipher MA. Hypogammaglobulinemia due to CAR T-cell therapy. Pediatr Blood Cancer. 2018. https:\/\/doi.org\/10.1002\/pbc.26914.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"4185_CR50","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing <em>ERBB2<\/em>. Mol Ther. 2010;18(4):843\u201351. https:\/\/doi.org\/10.1038\/mt.2010.24.","journal-title":"Mol Ther"},{"issue":"4","key":"4185_CR51","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CH Lamers","year":"2013","unstructured":"Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4):904\u201312. https:\/\/doi.org\/10.1038\/mt.2013.17.","journal-title":"Mol Ther"},{"key":"4185_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2025.07.012","author":"PK Gupta","year":"2025","unstructured":"Gupta PK, Kumar S. Third-generation novel technologies for gene editing. Trends Biotechnol. 2025. https:\/\/doi.org\/10.1016\/j.tibtech.2025.07.012.","journal-title":"Trends Biotechnol"},{"key":"4185_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.780145","volume":"12","author":"S Smirnov","year":"2021","unstructured":"Smirnov S, Petukhov A, Levchuk K, Kulemzin S, Staliarova A, Lepik K, et al. Strategies to circumvent the side-effects of immunotherapy using allogeneic CAR-T cells and boost its efficacy: results of recent clinical trials. Front Immunol. 2021;12:780145. https:\/\/doi.org\/10.3389\/fimmu.2021.780145.","journal-title":"Front Immunol"},{"issue":"1","key":"4185_CR54","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40364-024-00602-z","volume":"12","author":"P Song","year":"2024","unstructured":"Song P, Zhang Q, Xu Z, Shi Y, Jing R, Luo D. CRISPR\/Cas-based CAR-T cells: production and application. Biomark Res. 2024;12(1):54. https:\/\/doi.org\/10.1186\/s40364-024-00602-z.","journal-title":"Biomark Res"},{"key":"4185_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2022.03.018","author":"J Kath","year":"2022","unstructured":"Kath J, Du W, Pruene A, Braun T, Thommandru B, Turk R, et al. Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells. Mole Ther Meth Clin Dev. 2022. https:\/\/doi.org\/10.1016\/j.omtm.2022.03.018.","journal-title":"Mole Ther Meth Clin Dev"},{"issue":"1","key":"4185_CR56","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1186\/s12967-024-05957-3","volume":"22","author":"W Xu","year":"2024","unstructured":"Xu W, Zhang S, Qin H, Yao K. From bench to bedside: cutting-edge applications of base editing and prime editing in precision medicine. J Transl Med. 2024;22(1):1133. https:\/\/doi.org\/10.1186\/s12967-024-05957-3.","journal-title":"J Transl Med"},{"issue":"6580","key":"4185_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj4008","volume":"375","author":"R Schmidt","year":"2022","unstructured":"Schmidt R, Steinhart Z, Layeghi M, Freimer JW, Bueno R, Nguyen VQ, et al. CRISPR activation and interference screens decode stimulation responses in primary human T cells. Science. 2022;375(6580):eabj4008. https:\/\/doi.org\/10.1126\/science.abj4008.","journal-title":"Science"},{"key":"4185_CR58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40164-020-00166-2","volume":"9","author":"L Kang","year":"2020","unstructured":"Kang L, Tang X, Zhang J, Li M, Xu N, Qi W, et al. Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes. Exp Hematol Oncol. 2020;9:11. https:\/\/doi.org\/10.1186\/s40164-020-00166-2.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"4185_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2021.2016005","volume":"18","author":"H Zhang","year":"2022","unstructured":"Zhang H, Lv X, Kong Q, Tan Y. IL-6\/IFN-\u03b3 double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro. Hum Vaccin Immunother. 2022;18(1):1\u201314. https:\/\/doi.org\/10.1080\/21645515.2021.2016005.","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"4185_CR60","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133(7):697\u2013709. https:\/\/doi.org\/10.1182\/blood-2018-10-881722.","journal-title":"Blood"},{"key":"4185_CR61","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221988","author":"M-Y Lin","year":"2024","unstructured":"Lin M-Y, Nam E, Shih RM, Shafer A, Bouren A, Ayala Ceja M, et al. Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy. J Exp Med. 2024. https:\/\/doi.org\/10.1084\/jem.20221988.","journal-title":"J Exp Med"},{"issue":"1","key":"4185_CR62","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41421-021-00299-6","volume":"7","author":"L Xue","year":"2021","unstructured":"Xue L, Yi Y, Xu Q, Wang L, Yang X, Zhang Y, et al. Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy. Cell Discov. 2021;7(1):84. https:\/\/doi.org\/10.1038\/s41421-021-00299-6.","journal-title":"Cell Discov"},{"issue":"1","key":"4185_CR63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41421-021-00255-4","volume":"7","author":"Y Yi","year":"2021","unstructured":"Yi Y, Chai X, Zheng L, Zhang Y, Shen J, Hu B, et al. CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy. Cell Discov. 2021;7(1):27. https:\/\/doi.org\/10.1038\/s41421-021-00255-4.","journal-title":"Cell Discov"},{"issue":"1","key":"4185_CR64","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12935-024-03479-y","volume":"24","author":"S Mansoori","year":"2024","unstructured":"Mansoori S, Noei A, Maali A, Seyed-Motahari SS, Sharifzadeh Z. Recent updates on allogeneic CAR-T cells in hematological malignancies. Cancer Cell Int. 2024;24(1):304. https:\/\/doi.org\/10.1186\/s12935-024-03479-y.","journal-title":"Cancer Cell Int"},{"key":"4185_CR65","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.4485","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Yang J, Manoharan E, Yu AB, Milone MC. CRISPR\/Cas9-mediated gene knockout followed by negative selection leads to a complete TCR depletion in ortho CAR19 T cells. Bio Protoc. 2022. https:\/\/doi.org\/10.21769\/BioProtoc.4485.","journal-title":"Bio Protoc"},{"issue":"1","key":"4185_CR66","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s42003-025-07708-6","volume":"8","author":"NP Quast","year":"2025","unstructured":"Quast NP, Abanades B, Guloglu B, Karuppiah V, Harper S, Raybould MIJ, et al. T-cell receptor structures and predictive models reveal comparable alpha and beta chain structural diversity despite differing genetic complexity. Commun Biol. 2025;8(1):362. https:\/\/doi.org\/10.1038\/s42003-025-07708-6.","journal-title":"Commun Biol"},{"issue":"24","key":"4185_CR67","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","volume":"119","author":"H Torikai","year":"2012","unstructured":"Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119(24):5697\u2013705. https:\/\/doi.org\/10.1182\/blood-2012-01-405365.","journal-title":"Blood"},{"key":"4185_CR68","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3389\/fbioe.2020.00678","volume":"8","author":"A Juillerat","year":"2020","unstructured":"Juillerat A, Tkach D, Yang M, Boyne A, Valton J, Poirot L, et al. Straightforward generation of ultrapure off-the-shelf allogeneic CAR-T cells. Front Bioeng Biotechnol. 2020;8:678. https:\/\/doi.org\/10.3389\/fbioe.2020.00678.","journal-title":"Front Bioeng Biotechnol"},{"issue":"10","key":"4185_CR69","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jcyt.2013.05.014","volume":"15","author":"M Schumm","year":"2013","unstructured":"Schumm M, Lang P, Bethge W, Faul C, Feuchtinger T, Pfeiffer M, et al. Depletion of T-cell receptor alpha\/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy. 2013;15(10):1253\u20138. https:\/\/doi.org\/10.1016\/j.jcyt.2013.05.014.","journal-title":"Cytotherapy"},{"issue":"374","key":"4185_CR70","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013","volume":"9","author":"W Qasim","year":"2017","unstructured":"Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(374):eaaj2013. https:\/\/doi.org\/10.1126\/scitranslmed.aaj2013.","journal-title":"Sci Transl Med"},{"issue":"11","key":"4185_CR71","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/s2352-3026(22)00245-9","volume":"9","author":"R Benjamin","year":"2022","unstructured":"Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. 2022;9(11):e833\u201343. https:\/\/doi.org\/10.1016\/s2352-3026(22)00245-9.","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"4185_CR72","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.1182\/blood-2022-158231","volume":"140","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Matous JV, Liedtke M, Sidana S, Oluwole OO, Mohan M, et al. Universal updated phase 1 data highlights role of allogeneic anti-BCMA ALLO-715 therapy for relapsed\/refractory multiple myeloma. Blood. 2022;140(Supplement 1):4620\u20132. https:\/\/doi.org\/10.1182\/blood-2022-158231.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4185_CR73","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1182\/blood-2021-146038","volume":"138","author":"SS Neelapu","year":"2021","unstructured":"Neelapu SS, Nath R, Munoz J, Tees M, Miklos DB, Frank MJ, et al. ALPHA study: ALLO-501 produced deep and durable responses in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma comparable to autologous CAR T. Blood. 2021;138(Supplement 1):3878. https:\/\/doi.org\/10.1182\/blood-2021-146038.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4185_CR74","doi-asserted-by":"publisher","first-page":"10303","DOI":"10.1182\/blood-2022-166432","volume":"140","author":"JP McGuirk","year":"2022","unstructured":"McGuirk JP, Tam CS, Kr\u00f6ger N, Riedell PA, Murthy HS, Ho PJ, et al. CTX110 allogeneic CRISPR-Cas9-engineered CAR T cells in patients (Pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): results from the phase 1 dose escalation carbon study. Blood. 2022;140(Supplement 1):10303\u20136. https:\/\/doi.org\/10.1182\/blood-2022-166432.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4185_CR75","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1182\/blood-2021-153166","volume":"138","author":"N Jain","year":"2021","unstructured":"Jain N, Kantarjian H, Solomon SR, He F, Sauter CS, Heery CR, et al. Preliminary safety and efficacy of PBCAR0191, an allogeneic \u201coff-the-shelf\u201d CD19-directed CAR-T for patients with relapsed\/refractory (R\/R) CD19+ B-ALL. Blood. 2021;138(Supplement 1):650. https:\/\/doi.org\/10.1182\/blood-2021-153166.","journal-title":"Blood"},{"key":"4185_CR76","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2020-138594","volume":"136","author":"N Jain","year":"2020","unstructured":"Jain N, Roboz GJ, Konopleva M, Liu H, Jabbour E, Poirot C, et al. Preliminary results of Balli-01: a phase I study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in adult patients with relapsed or refractory (R\/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood. 2020;136:7\u20138. https:\/\/doi.org\/10.1182\/blood-2020-138594.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4185_CR77","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1182\/blood-2022-167194","volume":"140","author":"A Mehta","year":"2022","unstructured":"Mehta A, Farooq U, Chen A, McGuirk JP, Ly T, Wong L, et al. Interim phase I clinical data of FT819-101, a study of the first-ever, off-the-shelf, iPSC-derived TCR-less CD19 CAR T-cell therapy for patients with relapsed\/refractory B-cell malignancies. Blood. 2022;140(Supplement 1):4577\u20138. https:\/\/doi.org\/10.1182\/blood-2022-167194.","journal-title":"Blood"},{"key":"4185_CR78","unstructured":"Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress [press release]. 06 Dec, 2022 2022."},{"issue":"Supplement 1","key":"4185_CR79","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1182\/blood-2024-207459","volume":"144","author":"B Dholaria","year":"2024","unstructured":"Dholaria B, Shune LO, Kocoglu MH, Kin A, Ramakrishnan A, Malek E, et al. A phase 1 study of P-BCMA-ALLO1, a non-viral, allogeneic BCMA directed CAR-T in relapsed\/refractory multiple myeloma (RRMM): results from optimized lymphodepletion cohort. Blood. 2024;144(Supplement 1):4828. https:\/\/doi.org\/10.1182\/blood-2024-207459.","journal-title":"Blood"},{"key":"4185_CR80","unstructured":"Ottaviano G, Georgiadis C, Gkazi SA, Syed F, Zhan H, Etuk A, et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci Transl Med. 2022;14(668):eabq3010. 10.1126\/scitranslmed.abq3010"},{"issue":"Supplement 1","key":"4185_CR81","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2020-142262","volume":"136","author":"Y Hu","year":"2020","unstructured":"Hu Y, Zhou Y, Zhang M, Ge W, Li Y, Yang L, et al. The safety and efficacy of a CRISPR\/Cas9-engineered universal CAR-T cell product (CTA101) in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood. 2020;136(Supplement 1):52. https:\/\/doi.org\/10.1182\/blood-2020-142262.","journal-title":"Blood"},{"issue":"11","key":"4185_CR82","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32(11):995\u20131007. https:\/\/doi.org\/10.1038\/s41422-022-00721-y.","journal-title":"Cell Res"},{"key":"4185_CR83","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/01.HS9.0000844368.41871.e3","volume":"6","author":"S Li","year":"2022","unstructured":"Li S, Yuan Z, Liu L, Li Y, Martina S, Liu J, et al. P370: early results of a safety and efficacy study of allogeneic TRUUCAR\u2122 GC502 in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL). HemaSphere. 2022;6:270\u20131. https:\/\/doi.org\/10.1097\/01.HS9.0000844368.41871.e3.","journal-title":"HemaSphere"},{"key":"4185_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1110482","author":"M Barden","year":"2023","unstructured":"Barden M, Holzinger A, Velas L, Mez\u0151si-Csapl\u00e1r M, Sz\u00f6\u0151r \u00c1, Vereb G, et al. CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1110482.","journal-title":"Front Immunol"},{"issue":"12","key":"4185_CR85","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood.2020005185","volume":"136","author":"D Stenger","year":"2020","unstructured":"Stenger D, Stief TA, Kaeuferle T, Willier S, Rataj F, Schober K, et al. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR. Blood. 2020;136(12):1407\u201318. https:\/\/doi.org\/10.1182\/blood.2020005185.","journal-title":"Blood"},{"issue":"9","key":"4185_CR86","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","volume":"18","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18(9):2188\u201398. https:\/\/doi.org\/10.1038\/s41423-021-00749-x.","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"4185_CR87","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s40259-024-00654-5","volume":"38","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Zhang S, Wong HT, Li D, Feng B. Targeted gene insertion: the cutting edge of CRISPR drug development with hemophilia as a highlight. BioDrugs. 2024;38(3):369\u201385. https:\/\/doi.org\/10.1007\/s40259-024-00654-5.","journal-title":"BioDrugs"},{"issue":"7643","key":"4185_CR88","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJC, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113\u20137. https:\/\/doi.org\/10.1038\/nature21405.","journal-title":"Nature"},{"issue":"4","key":"4185_CR89","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.ymthe.2025.02.028","volume":"33","author":"Y Wang","year":"2025","unstructured":"Wang Y, Jiang J, Shang K, Xu X, Sun J. Turning, \u201ctrashed\u201d genomic loci into treasurable sites for integrating chimeric antigen receptors in T and NK cells. Mol Ther. 2025;33(4):1368\u201379. https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.028.","journal-title":"Mol Ther"},{"key":"4185_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/v15010202","author":"FH Rothemejer","year":"2023","unstructured":"Rothemejer FH, Lauritsen NP, Juhl AK, Schleimann MH, K\u00f6nig S, S\u00f8gaard OS, et al. Development of HIV-resistant CAR T cells by CRISPR\/Cas-mediated CAR integration into the CCR5 locus. Viruses. 2023. https:\/\/doi.org\/10.3390\/v15010202.","journal-title":"Viruses"},{"key":"4185_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031689","author":"A Rezalotfi","year":"2022","unstructured":"Rezalotfi A, Fritz L, F\u00f6rster R, Bo\u0161njak B. Challenges of CRISPR-based gene editing in primary T cells. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23031689.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4185_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102344","volume":"35","author":"H Liao","year":"2024","unstructured":"Liao H, Wu J, VanDusen NJ, Li Y, Zheng Y. CRISPR-Cas9-mediated homology-directed repair for precise gene editing. Mol Ther Nucleic Acids. 2024;35(4):102344. https:\/\/doi.org\/10.1016\/j.omtn.2024.102344.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"4185_CR93","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1038\/s41467-023-40344-4","volume":"14","author":"S Wimberger","year":"2023","unstructured":"Wimberger S, Akrap N, Firth M, Brengdahl J, Engberg S, Schwinn MK, et al. Simultaneous inhibition of DNA-PK and Pol\u03f4 improves integration efficiency and precision of genome editing. Nat Commun. 2023;14(1):4761. https:\/\/doi.org\/10.1038\/s41467-023-40344-4.","journal-title":"Nat Commun"},{"key":"4185_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-019-0329-7","author":"X Dai","year":"2019","unstructured":"Dai X, Park J, Du Y, Kim H, Wang G, Errami Y, et al. One-step generation of modular CAR-T cells with AAV\u2013Cpf1. Nat Methods. 2019. https:\/\/doi.org\/10.1038\/s41592-019-0329-7.","journal-title":"Nat Methods"},{"issue":"1","key":"4185_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00509-1","volume":"11","author":"H Dabiri","year":"2023","unstructured":"Dabiri H, Safarzadeh Kozani P, Habibi Anbouhi M, Mirzaee Godarzee M, Haddadi MH, Basiri M, et al. Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies. Biomark Res. 2023;11(1):67. https:\/\/doi.org\/10.1186\/s40364-023-00509-1.","journal-title":"Biomark Res"},{"key":"4185_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98965-y","author":"M Schubert","year":"2021","unstructured":"Schubert M, Thommandru B, Woodley J, Turk R, Yan S, Kurgan G, et al. Optimized design parameters for CRISPR Cas9 and Cas12a homology-directed repair. Sci Rep. 2021. https:\/\/doi.org\/10.1038\/s41598-021-98965-y.","journal-title":"Sci Rep"},{"issue":"1","key":"4185_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00602-z","volume":"12","author":"P Song","year":"2024","unstructured":"Song P, Zhang Q, Xu Z, Shi Y, Jing R, Luo D. CRISPR\/Cas-based CAR-T cells: production and application. Biomark Res. 2024;12(1):54. https:\/\/doi.org\/10.1186\/s40364-024-00602-z.","journal-title":"Biomark Res"},{"issue":"5","key":"4185_CR98","doi-asserted-by":"publisher","DOI":"10.1007\/s11538-021-00869-5","volume":"83","author":"K Owens","year":"2021","unstructured":"Owens K, Bozic I. Modeling CAR T-cell therapy with patient preconditioning. Bull Math Biol. 2021;83(5):42. https:\/\/doi.org\/10.1007\/s11538-021-00869-5.","journal-title":"Bull Math Biol"},{"key":"4185_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1398078","author":"S Arya","year":"2024","unstructured":"Arya S, Shahid Z. Overview of infectious complications among CAR T- cell therapy recipients. Front Oncol. 2024. https:\/\/doi.org\/10.3389\/fonc.2024.1398078.","journal-title":"Front Oncol"},{"issue":"4","key":"4185_CR100","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/cad.0000000000001485","volume":"34","author":"Z Gao","year":"2023","unstructured":"Gao Z, Lian Y, Ti J, Ren R, Ma L. Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy. Anticancer Drugs. 2023;34(4):551\u20137. https:\/\/doi.org\/10.1097\/cad.0000000000001485.","journal-title":"Anticancer Drugs"},{"key":"4185_CR101","doi-asserted-by":"publisher","first-page":"1491282","DOI":"10.3389\/fcell.2024.1491282","volume":"12","author":"M Alidadi","year":"2024","unstructured":"Alidadi M, Barzgar H, Zaman M, Paevskaya OA, Metanat Y, Khodabandehloo E, et al. Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects. Front Cell Dev Biol. 2024;12:1491282. https:\/\/doi.org\/10.3389\/fcell.2024.1491282.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"4185_CR102","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","volume":"13","author":"S Jo","year":"2022","unstructured":"Jo S, Das S, Williams A, Chretien A-S, Pagliardini T, Le Roy A, et al. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. Nat Commun. 2022;13(1):3453. https:\/\/doi.org\/10.1038\/s41467-022-30896-2.","journal-title":"Nat Commun"},{"key":"4185_CR103","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.omtm.2022.05.010","volume":"26","author":"Y Kitano","year":"2022","unstructured":"Kitano Y, Nishimura S, Kato TM, Ueda A, Takigawa K, Umekage M, et al. Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application. Mole Ther Meth Clin Dev. 2022;26:15\u201325. https:\/\/doi.org\/10.1016\/j.omtm.2022.05.010.","journal-title":"Mole Ther Meth Clin Dev"},{"issue":"4","key":"4185_CR104","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","volume":"24","author":"H Xu","year":"2019","unstructured":"Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N, et al. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility. Cell Stem Cell. 2019;24(4):566-78.e7. https:\/\/doi.org\/10.1016\/j.stem.2019.02.005.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"4185_CR105","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399. https:\/\/doi.org\/10.1038\/s41573-019-0051-2.","journal-title":"Nat Rev Drug Discov"},{"key":"4185_CR106","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005857","author":"AN Beckett","year":"2023","unstructured":"Beckett AN, Chockley P, Pruett-Miller SM, Nguyen P, Vogel P, Sheppard H, et al. CD47 expression is critical for CAR T-cell survival in vivo. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-005857.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4185_CR107","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.stem.2013.11.014","volume":"14","author":"Z Rong","year":"2014","unstructured":"Rong Z, Wang M, Hu Z, Stradner M, Zhu S, Kong H, et al. An effective approach to prevent immune rejection of human ESC-derived allografts. Cell Stem Cell. 2014;14(1):121\u201330. https:\/\/doi.org\/10.1016\/j.stem.2013.11.014.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"4185_CR108","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41551-021-00730-z","volume":"5","author":"B Wang","year":"2021","unstructured":"Wang B, Iriguchi S, Waseda M, Ueda N, Ueda T, Xu H, et al. Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nat Biomed Eng. 2021;5(5):429\u201340. https:\/\/doi.org\/10.1038\/s41551-021-00730-z.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"4185_CR109","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","volume":"39","author":"F Mo","year":"2021","unstructured":"Mo F, Watanabe N, McKenna MK, Hicks MJ, Srinivasan M, Gomes-Silva D, et al. Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021;39(1):56\u201363. https:\/\/doi.org\/10.1038\/s41587-020-0601-5.","journal-title":"Nat Biotechnol"},{"key":"4185_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1090959","volume":"13","author":"S Thomas","year":"2022","unstructured":"Thomas S, Abken H. CAR T cell therapy becomes CHIC: \u201ccytokine help intensified CAR\u201d T cells. Front Immunol. 2022;13:1090959. https:\/\/doi.org\/10.3389\/fimmu.2022.1090959.","journal-title":"Front Immunol"},{"issue":"2","key":"4185_CR111","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/intimm\/dxad033","volume":"36","author":"Y Kagoya","year":"2023","unstructured":"Kagoya Y. Cytokine signaling in chimeric antigen receptor T-cell therapy. Int Immunol. 2023;36(2):49\u201356. https:\/\/doi.org\/10.1093\/intimm\/dxad033.","journal-title":"Int Immunol"},{"issue":"20","key":"4185_CR112","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1158\/1078-0432.Ccr-20-0777","volume":"26","author":"H Luo","year":"2020","unstructured":"Luo H, Su J, Sun R, Sun Y, Wang Y, Dong Y, et al. Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion. Clin Cancer Res. 2020;26(20):5494\u2013505. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-0777.","journal-title":"Clin Cancer Res"},{"key":"4185_CR113","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000553","author":"A Silva","year":"2021","unstructured":"Silva A, Almeida A, Cachucho A, Neto J, Demeyer S, Matos M, et al. Overexpression of wild type IL-7R\u03b1 promotes T-cell acute lymphoblastic leukemia\/lymphoma. Blood. 2021. https:\/\/doi.org\/10.1182\/blood.2019000553.","journal-title":"Blood"},{"key":"4185_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217541","volume":"614","author":"Y Zhai","year":"2025","unstructured":"Zhai Y, Li G, Pan C, Yu M, Hu H, Wang D, et al. The development and potent antitumor efficacy of CD44\/CD133 dual-targeting IL7R\u03b1-armored CAR-T cells against glioblastoma. Cancer Lett. 2025;614:217541. https:\/\/doi.org\/10.1016\/j.canlet.2025.217541.","journal-title":"Cancer Lett"},{"issue":"6","key":"4185_CR115","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03685-7","volume":"73","author":"N Sakunrangsit","year":"2024","unstructured":"Sakunrangsit N, Khuisangeam N, Inthanachai T, Yodsurang V, Taechawattananant P, Suppipat K, et al. Incorporating IL7 receptor alpha signaling in the endodomain of B7H3-targeting chimeric antigen receptor T cells mediates antitumor activity in glioblastoma. Cancer Immunol Immunother. 2024;73(6):98. https:\/\/doi.org\/10.1007\/s00262-024-03685-7.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"4185_CR116","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1158\/2767-9764.Crc-24-0286","volume":"4","author":"SC Vorri","year":"2024","unstructured":"Vorri SC, Holl NJ, Leeming M, Apostolova P, Marple A, Ravich JW, et al. Activation of cell-intrinsic signaling in CAR-T cells via a chimeric IL7R domain. Cancer Res Commun. 2024;4(9):2359\u201373. https:\/\/doi.org\/10.1158\/2767-9764.Crc-24-0286.","journal-title":"Cancer Res Commun"},{"issue":"5","key":"4185_CR117","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.Cir-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo CF, et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res. 2019;7(5):759\u201372. https:\/\/doi.org\/10.1158\/2326-6066.Cir-18-0466.","journal-title":"Cancer Immunol Res"},{"key":"4185_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061704","author":"Z Od\u00e9","year":"2020","unstructured":"Od\u00e9 Z, Condori J, Peterson N, Zhou S, Krenciute G. CRISPR-mediated non-viral site-specific gene integration and expression in T cells: protocol and application for T-cell therapy. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12061704.","journal-title":"Cancers (Basel)"},{"issue":"8047","key":"4185_CR119","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025;637(8047):940\u20136. https:\/\/doi.org\/10.1038\/s41586-024-08261-8.","journal-title":"Nature"},{"issue":"7","key":"4185_CR120","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008572","volume":"12","author":"S-M In\u00e9s","year":"2024","unstructured":"In\u00e9s S-M, Aritz L-C, Celia M-O, Noelia C, Flor N, Marta G, et al. Tethered IL15-IL15R\u03b1 augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model. J Immunother Cancer. 2024;12(7):e008572. https:\/\/doi.org\/10.1136\/jitc-2023-008572.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"4185_CR121","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03756-9","volume":"73","author":"H Wu","year":"2024","unstructured":"Wu H, Xu Z, Qi M, Liu P, Zhang B, Wang Z, et al. Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma. Cancer Immunol Immunother. 2024;73(10):188. https:\/\/doi.org\/10.1007\/s00262-024-03756-9.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4185_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-16616-2","volume":"12","author":"L Li","year":"2022","unstructured":"Li L, Li Q, Yan Z-X, Sheng L-S, Fu D, Xu P, et al. Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells. Sci Rep. 2022;12(1):12506. https:\/\/doi.org\/10.1038\/s41598-022-16616-2.","journal-title":"Sci Rep"},{"issue":"1","key":"4185_CR123","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","volume":"14","author":"N Pang","year":"2021","unstructured":"Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H, et al. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021;14(1):118. https:\/\/doi.org\/10.1186\/s13045-021-01128-9.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"4185_CR124","doi-asserted-by":"publisher","DOI":"10.4161\/2162402x.2014.994446","volume":"4","author":"M Koneru","year":"2015","unstructured":"Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015;4(3):e994446. https:\/\/doi.org\/10.4161\/2162402x.2014.994446.","journal-title":"Oncoimmunology"},{"issue":"18","key":"4185_CR125","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119(18):4133\u201341. https:\/\/doi.org\/10.1182\/blood-2011-12-400044.","journal-title":"Blood"},{"key":"4185_CR126","doi-asserted-by":"publisher","DOI":"10.1172\/jci166028","author":"JE Jaspers","year":"2023","unstructured":"Jaspers JE, Khan JF, Godfrey WD, Lopez AV, Ciampricotti M, Rudin CM, et al. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/jci166028.","journal-title":"J Clin Invest"},{"issue":"2","key":"4185_CR127","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1182\/blood.2023022293","volume":"144","author":"BD Ng","year":"2024","unstructured":"Ng BD, Rajagopalan A, Kousa AI, Fischman JS, Chen S, Massa A, et al. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model. Blood. 2024;144(2):171\u201386. https:\/\/doi.org\/10.1182\/blood.2023022293.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4185_CR128","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1182\/blood-2022-162393","volume":"140","author":"J Svoboda","year":"2022","unstructured":"Svoboda J, Gerson JN, Landsburg DJ, Chong EA, Barta SK, Dwivedy Nasta S, et al. Interleukin-18 secreting autologous anti-CD19 CAR T-cells (huCART19-IL18) in patients with Non-Hodgkin lymphomas relapsed or refractory to prior CAR T-cell therapy. Blood. 2022;140(Supplement 1):4612\u20134. https:\/\/doi.org\/10.1182\/blood-2022-162393.","journal-title":"Blood"},{"issue":"12","key":"4185_CR129","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jcyt.2020.08.005","volume":"22","author":"M \u0160tach","year":"2020","unstructured":"\u0160tach M, Pt\u00e1\u010dkov\u00e1 P, Mucha M, Musil J, Klener P, Ot\u00e1hal P. Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells. Cytotherapy. 2020;22(12):744\u201354. https:\/\/doi.org\/10.1016\/j.jcyt.2020.08.005.","journal-title":"Cytotherapy"},{"issue":"1","key":"4185_CR130","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s10238-024-01473-2","volume":"24","author":"S Chen","year":"2024","unstructured":"Chen S, Gong F, Liu S, Xie Y, Ye X, Lin X, et al. IL-21- and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma. Clin Exp Med. 2024;24(1):204. https:\/\/doi.org\/10.1007\/s10238-024-01473-2.","journal-title":"Clin Exp Med"},{"key":"4185_CR131","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133977","author":"N Tang","year":"2020","unstructured":"Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W, et al. TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.133977.","journal-title":"JCI Insight"},{"issue":"1","key":"4185_CR132","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s12967-021-03146-0","volume":"19","author":"K Alishah","year":"2021","unstructured":"Alishah K, Birtel M, Masoumi E, Jafarzadeh L, Mirzaee HR, Hadjati J, et al. CRISPR\/Cas9-mediated TGF\u03b2RII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro. J Transl Med. 2021;19(1):482. https:\/\/doi.org\/10.1186\/s12967-021-03146-0.","journal-title":"J Transl Med"},{"issue":"Supplement 1","key":"4185_CR133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182516","volume":"142","author":"H Chen","year":"2023","unstructured":"Chen H, He B, Zhong S, Huang D, Deng S, Liu Q, et al. Disruption of SOCS1 promotes the antitumor activity of CD19-specific CAR NK cells coexpressing IL-15. Blood. 2023;142(Supplement 1):6829-. https:\/\/doi.org\/10.1182\/blood-2023-182516.","journal-title":"Blood"},{"issue":"8","key":"4185_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112940","volume":"42","author":"S Mise-Omata","year":"2023","unstructured":"Mise-Omata S, Ando M, Srirat T, Nakagawara K, Hayakawa T, Iizuka-Koga M, et al. SOCS3 deletion in effector T cells confers an anti-tumorigenic role of IL-6 to the pro-tumorigenic cytokine. Cell Rep. 2023;42(8):112940. https:\/\/doi.org\/10.1016\/j.celrep.2023.112940.","journal-title":"Cell Rep"},{"key":"4185_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16091228","author":"X Kang","year":"2024","unstructured":"Kang X, Mita N, Zhou L, Wu S, Yue Z, Babu RJ, et al. Nanotechnology in advancing chimeric antigen receptor T cell therapy for cancer treatment. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16091228.","journal-title":"Pharmaceutics"},{"issue":"3","key":"4185_CR136","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s13770-022-00515-8","volume":"20","author":"S Shin","year":"2023","unstructured":"Shin S, Lee P, Han J, Kim SN, Lim J, Park DH, et al. Nanoparticle-based chimeric antigen receptor therapy for cancer immunotherapy. Tissue Eng Regen Med. 2023;20(3):371\u201387. https:\/\/doi.org\/10.1007\/s13770-022-00515-8.","journal-title":"Tissue Eng Regen Med"},{"issue":"3","key":"4185_CR137","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbae017","volume":"7","author":"EM Jacob","year":"2024","unstructured":"Jacob EM, Huang J, Chen M. Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology. Precis Clin Med. 2024;7(3):pbae017. https:\/\/doi.org\/10.1093\/pcmedi\/pbae017.","journal-title":"Precis Clin Med"},{"issue":"23","key":"4185_CR138","doi-asserted-by":"publisher","first-page":"21206","DOI":"10.1021\/acsnano.4c18274","volume":"19","author":"A Udepurkar","year":"2025","unstructured":"Udepurkar A, Devos C, Sagmeister P, Destro F, Inguva P, Ahmadi S, et al. Structure and morphology of lipid nanoparticles for nucleic acid drug delivery: a review. ACS Nano. 2025;19(23):21206\u201342. https:\/\/doi.org\/10.1021\/acsnano.4c18274.","journal-title":"ACS Nano"},{"issue":"33","key":"4185_CR139","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2303567120","volume":"120","author":"SJ Shepherd","year":"2023","unstructured":"Shepherd SJ, Han X, Mukalel AJ, El-Mayta R, Thatte AS, Wu J, et al. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines. Proc Natl Acad Sci USA. 2023;120(33):e2303567120. https:\/\/doi.org\/10.1073\/pnas.2303567120.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"4185_CR140","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1021\/acs.nanolett.1c02503","volume":"22","author":"MM Billingsley","year":"2022","unstructured":"Billingsley MM, Hamilton AG, Mai D, Patel SK, Swingle KL, Sheppard NC, et al. Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells. Nano Lett. 2022;22(1):533\u201342. https:\/\/doi.org\/10.1021\/acs.nanolett.1c02503.","journal-title":"Nano Lett"},{"issue":"3","key":"4185_CR141","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","volume":"20","author":"MM Billingsley","year":"2020","unstructured":"Billingsley MM, Singh N, Ravikumar P, Zhang R, June CH, Mitchell MJ. Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. Nano Lett. 2020;20(3):1578\u201389. https:\/\/doi.org\/10.1021\/acs.nanolett.9b04246.","journal-title":"Nano Lett"},{"key":"4185_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101139","volume":"31","author":"R Kitte","year":"2023","unstructured":"Kitte R, Rabel M, Geczy R, Park S, Fricke S, Koehl U, et al. Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering. Mol Ther Methods Clin Dev. 2023;31:101139. https:\/\/doi.org\/10.1016\/j.omtm.2023.101139.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"4185_CR143","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjh.19988","volume":"206","author":"Z Chen","year":"2025","unstructured":"Chen Z, Ren A, Li Y, Shu J, Wu J, Huang H, et al. mRNA\u2010laden lipid nanoparticle\u2010enabled humanized CD19 CAR\u2010T\u2010cell engineering for the eradication of leukaemic cells. Br J Haematol. 2025;206(2):628\u201343. https:\/\/doi.org\/10.1111\/bjh.19988.","journal-title":"Br J Haematol"},{"issue":"26","key":"4185_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202313226","volume":"36","author":"AE Metzloff","year":"2024","unstructured":"Metzloff AE, Padilla MS, Gong N, Billingsley MM, Han X, Merolle M, et al. Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy. Adv Mater. 2024;36(26):e2313226. https:\/\/doi.org\/10.1002\/adma.202313226.","journal-title":"Adv Mater"},{"issue":"1","key":"4185_CR145","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00625-8","volume":"14","author":"J Cai","year":"2025","unstructured":"Cai J, Liu Z, Chen S, Zhang J, Li H, Wang X, et al. Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer. Exp Hematol Oncol. 2025;14(1):35. https:\/\/doi.org\/10.1186\/s40164-025-00625-8.","journal-title":"Exp Hematol Oncol"},{"key":"4185_CR146","doi-asserted-by":"publisher","DOI":"10.3390\/v17040566","author":"T Vallet","year":"2025","unstructured":"Vallet T, Vignuzzi M. Self-amplifying RNA: advantages and challenges of a versatile platform for vaccine development. Viruses. 2025. https:\/\/doi.org\/10.3390\/v17040566.","journal-title":"Viruses"},{"key":"4185_CR147","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.2147\/ijn.S424723","volume":"18","author":"P Prazeres","year":"2023","unstructured":"Prazeres P, Ferreira H, Costa PAC, da Silva W, Alves MT, Padilla M, et al. Delivery of Plasmid DNA by Ionizable Lipid Nanoparticles to Induce CAR Expression in T Cells. Int J Nanomedicine. 2023;18:5891\u2013904. https:\/\/doi.org\/10.2147\/ijn.S424723.","journal-title":"Int J Nanomedicine"},{"issue":"9","key":"4185_CR148","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","volume":"124","author":"MA Beach","year":"2024","unstructured":"Beach MA, Nayanathara U, Gao Y, Zhang C, Xiong Y, Wang Y, et al. Polymeric nanoparticles for drug delivery. Chem Rev. 2024;124(9):5505\u2013616. https:\/\/doi.org\/10.1021\/acs.chemrev.3c00705.","journal-title":"Chem Rev"},{"issue":"7","key":"4185_CR149","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1039\/d3nr05768b","volume":"16","author":"Y Lin","year":"2024","unstructured":"Lin Y, Chen Y, Luo Z, Wu YL. Recent advances in biomaterial designs for assisting CAR-T cell therapy towards potential solid tumor treatment. Nanoscale. 2024;16(7):3226\u201342. https:\/\/doi.org\/10.1039\/d3nr05768b.","journal-title":"Nanoscale"},{"key":"4185_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030775","author":"Z Yu","year":"2023","unstructured":"Yu Z, Shen X, Yu H, Tu H, Chittasupho C, Zhao Y. Smart polymeric nanoparticles in cancer immunotherapy. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15030775.","journal-title":"Pharmaceutics"},{"issue":"6","key":"4185_CR151","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/molecules24061035","volume":"24","author":"J Pan","year":"2019","unstructured":"Pan J, Rostamizadeh K, Filipczak N, Torchilin VP. Polymeric co-delivery systems in cancer treatment: an overview on component drugs\u2019 dosage ratio effect. Molecules. 2019;24(6):1035.","journal-title":"Molecules"},{"issue":"1","key":"4185_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2025.101015","volume":"20","author":"J Zhang","year":"2025","unstructured":"Zhang J, Yang X, Chang Z, Zhu W, Ma Y, He H. Polymeric nanocarriers for therapeutic gene delivery. Asian J Pharm Sci. 2025;20(1):101015. https:\/\/doi.org\/10.1016\/j.ajps.2025.101015.","journal-title":"Asian J Pharm Sci"},{"issue":"1","key":"4185_CR153","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12967-024-06052-3","volume":"23","author":"E Pinto","year":"2025","unstructured":"Pinto E, Lione L, Compagnone M, Paccagnella M, Salvatori E, Greco M, et al. From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy. J Transl Med. 2025;23(1):10. https:\/\/doi.org\/10.1186\/s12967-024-06052-3.","journal-title":"J Transl Med"},{"key":"4185_CR154","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.canlet.2021.02.011","volume":"505","author":"R Munagala","year":"2021","unstructured":"Munagala R, Aqil F, Jeyabalan J, Kandimalla R, Wallen M, Tyagi N, et al. Exosome-mediated delivery of RNA and DNA for gene therapy. Cancer Lett. 2021;505:58\u201372. https:\/\/doi.org\/10.1016\/j.canlet.2021.02.011.","journal-title":"Cancer Lett"},{"key":"4185_CR155","doi-asserted-by":"publisher","DOI":"10.3390\/cells12101416","author":"H Zeng","year":"2023","unstructured":"Zeng H, Guo S, Ren X, Wu Z, Liu S, Yao X. Current strategies for exosome cargo loading and targeting delivery. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12101416.","journal-title":"Cells"},{"issue":"6","key":"4185_CR156","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jcyt.2023.01.005","volume":"25","author":"K Si","year":"2023","unstructured":"Si K, Dai Z, Li Z, Ye Z, Ding B, Feng S, et al. Engineered exosome-mediated messenger RNA and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering. Cytotherapy. 2023;25(6):615\u201324. https:\/\/doi.org\/10.1016\/j.jcyt.2023.01.005.","journal-title":"Cytotherapy"},{"key":"4185_CR157","doi-asserted-by":"publisher","unstructured":"Maeki M, Tokeshi M. (2025) Engineered and Artificial Exosomes for Non-viral Drug Delivery Nanocarriers. p. 275\u201390. https:\/\/doi.org\/10.1007\/978-981-97-7067-0_19","DOI":"10.1007\/978-981-97-7067-0_19"},{"issue":"27","key":"4185_CR158","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1080\/17435889.2024.2395239","volume":"19","author":"V Mohammadi","year":"2024","unstructured":"Mohammadi V, Esmaeilzadeh K, Esmaeilzadeh A. Application of magnetic nanoparticles in adoptive cell therapy of cancer; training, guiding and imaging cells. Nanomedicine (Lond). 2024;19(27):2315\u201329. https:\/\/doi.org\/10.1080\/17435889.2024.2395239.","journal-title":"Nanomedicine (Lond)"},{"issue":"8","key":"4185_CR159","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.apsb.2021.03.023","volume":"11","author":"NB Day","year":"2021","unstructured":"Day NB, Wixson WC, Shields CWt. Magnetic systems for cancer immunotherapy. Acta Pharm Sin B. 2021;11(8):2172\u201396. https:\/\/doi.org\/10.1016\/j.apsb.2021.03.023.","journal-title":"Acta Pharm Sin B"},{"key":"4185_CR160","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02616-z","volume":"22","author":"A Latypova","year":"2024","unstructured":"Latypova A, Yaremenko A, Pechnikova N, Minin A, Zubarev I. Magnetogenetics as a promising tool for controlling cellular signaling pathways. J Nanobiotechnology. 2024;22:327. https:\/\/doi.org\/10.1186\/s12951-024-02616-z.","journal-title":"J Nanobiotechnology"},{"issue":"1","key":"4185_CR161","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.tibtech.2024.07.014","volume":"43","author":"J Huang","year":"2025","unstructured":"Huang J, Fussenegger M. Programming mammalian cell behaviors by physical cues. Trends Biotechnol. 2025;43(1):16\u201342. https:\/\/doi.org\/10.1016\/j.tibtech.2024.07.014.","journal-title":"Trends Biotechnol"},{"key":"4185_CR162","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12090812","author":"L Sanz-Ortega","year":"2020","unstructured":"Sanz-Ortega L, Rojas JM, Barber DF. Improving tumor retention of effector cells in adoptive cell transfer therapies by magnetic targeting. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12090812.","journal-title":"Pharmaceutics"},{"key":"4185_CR163","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/B978-0-12-803581-8.10462-X","volume-title":"Comprehensive Nanoscience and Nanotechnology","author":"TD Clemons","year":"2019","unstructured":"Clemons TD, Kerr RH, Joos A. 3.10 \u2013 Multifunctional Magnetic Nanoparticles Design, Synthesis, and Biomedical Applications. In: Andrews DL, Lipson RH, Nann T, editors. Comprehensive Nanoscience and Nanotechnology. 2nd ed. Oxford: Academic Press; 2019. p. 193\u2013210.","edition":"2"},{"issue":"8","key":"4185_CR164","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.3390\/molecules29081824","volume":"29","author":"VC Ferreira-Filho","year":"2024","unstructured":"Ferreira-Filho VC, Morais B, Vieira BJC, Waerenborgh JC, Carmezim MJ, T\u00f3th CN, et al. Influence of SPION surface coating on magnetic properties and theranostic profile. Molecules. 2024;29(8):1824.","journal-title":"Molecules"},{"issue":"1","key":"4185_CR165","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/jnt1010008","volume":"1","author":"NR Nelson","year":"2020","unstructured":"Nelson NR, Port JD, Pandey MK. Use of superparamagnetic iron oxide nanoparticles (SPIONs) via multiple imaging modalities and modifications to reduce cytotoxicity: an educational review. Journal of Nanotheranostics. 2020;1(1):105\u201335.","journal-title":"Journal of Nanotheranostics"},{"key":"4185_CR166","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.addr.2010.05.006","volume":"63","author":"M Mahmoudi","year":"2011","unstructured":"Mahmoudi M, Sant S, Wang B, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONS): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev. 2011;63:24\u201346. https:\/\/doi.org\/10.1016\/j.addr.2010.05.006.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"4185_CR167","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.7150\/thno.15102","volume":"6","author":"H Jin","year":"2016","unstructured":"Jin H, Qian Y, Dai Y, Qiao S, Huang C, Lu L, et al. Magnetic enrichment of dendritic cell vaccine in lymph node with fluorescent-magnetic nanoparticles enhanced cancer immunotherapy. Theranostics. 2016;6(11):2000\u201314. https:\/\/doi.org\/10.7150\/thno.15102.","journal-title":"Theranostics"},{"issue":"9","key":"4185_CR168","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1039\/c4nr05791k","volume":"7","author":"D Tukmachev","year":"2015","unstructured":"Tukmachev D, Lunov O, Zablotskii V, Dejneka A, Babic M, Sykov\u00e1 E, et al. An effective strategy of magnetic stem cell delivery for spinal cord injury therapy. Nanoscale. 2015;7(9):3954\u20138. https:\/\/doi.org\/10.1039\/c4nr05791k.","journal-title":"Nanoscale"},{"key":"4185_CR169","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.2147\/ijn.S52135","volume":"8","author":"H Su","year":"2013","unstructured":"Su H, Mou Y, An Y, Han W, Huang X, Xia G, et al. The migration of synthetic magnetic nanoparticle labeled dendritic cells into lymph nodes with optical imaging. Int J Nanomedicine. 2013;8:3737\u201344. https:\/\/doi.org\/10.2147\/ijn.S52135.","journal-title":"Int J Nanomedicine"},{"issue":"4","key":"4185_CR170","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/cmmi.433","volume":"6","author":"SN de Chickera","year":"2011","unstructured":"de Chickera SN, Snir J, Willert C, Rohani R, Foley R, Foster PJ, et al. Labelling dendritic cells with SPIO has implications for their subsequent in vivo migration as assessed with cellular MRI. Contrast Media Mol Imaging. 2011;6(4):314\u201327. https:\/\/doi.org\/10.1002\/cmmi.433.","journal-title":"Contrast Media Mol Imaging"},{"issue":"2","key":"4185_CR171","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1073\/pnas.0708338105","volume":"105","author":"B Polyak","year":"2008","unstructured":"Polyak B, Fishbein I, Chorny M, Alferiev I, Williams D, Yellen B, et al. High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc Natl Acad Sci U S A. 2008;105(2):698\u2013703. https:\/\/doi.org\/10.1073\/pnas.0708338105.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4185_CR172","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70039","volume":"6","author":"F Pfister","year":"2025","unstructured":"Pfister F, Carnell LR, L\u00f6ffler L, Boosz P, Schaft N, D\u00f6rrie J, et al. Loading of CAR-T cells with magnetic nanoparticles for controlled targeting suppresses inflammatory cytokine release and switches tumor cell death mechanism. MedComm. 2025;6(1):e70039. https:\/\/doi.org\/10.1002\/mco2.70039.","journal-title":"MedComm"},{"issue":"5","key":"4185_CR173","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202414368","volume":"35","author":"H Chen","year":"2025","unstructured":"Chen H, Machado A, An D, Becharef S, Autret G, Ayollo D, et al. In vivo monitoring and magnetically-enhanced delivery of CAR T-cells to solid tumor. Adv Funct Mater. 2025;35(5):2414368. https:\/\/doi.org\/10.1002\/adfm.202414368.","journal-title":"Adv Funct Mater"},{"key":"4185_CR174","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102363119","author":"L Kiru","year":"2022","unstructured":"Kiru L, Zlitni A, Tousley AM, Dalton GN, Wu W, Lafortune F, et al. In vivo imaging of nanoparticle-labeled CAR T cells. Proc Natl Acad Sci U S A. 2022. https:\/\/doi.org\/10.1073\/pnas.2102363119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"4185_CR175","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202211509","volume":"35","author":"X Tang","year":"2023","unstructured":"Tang X, Yang Y, Zheng M, Yin T, Huang G, Lai Z, et al. Magnetic-acoustic sequentially actuated CAR T cell microrobots for precision navigation and in situ antitumor immunoactivation. Adv Mater. 2023;35(18):e2211509. https:\/\/doi.org\/10.1002\/adma.202211509.","journal-title":"Adv Mater"},{"issue":"5, Supplement","key":"4185_CR176","doi-asserted-by":"publisher","first-page":"S201","DOI":"10.1016\/j.jcyt.2020.04.074","volume":"22","author":"R Singla","year":"2020","unstructured":"Singla R, Wall D, Anderson S, Zia N, Korte J, Kravets L, et al. First in human study of in-vivo imaging of ex-vivo labelled CAR T cells with dual PET-MR. Cytotherapy. 2020;22(5, Supplement):S201. https:\/\/doi.org\/10.1016\/j.jcyt.2020.04.074.","journal-title":"Cytotherapy"},{"key":"4185_CR177","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16091228","volume":"16","author":"X Kang","year":"2024","unstructured":"Kang X, Mita N, Zhou L, Wu S, Yue Z, Babu RJ, et al. Nanotechnology in advancing chimeric antigen receptor T cell therapy for cancer treatment. Pharmaceutics. 2024;16:1228. https:\/\/doi.org\/10.3390\/pharmaceutics16091228.","journal-title":"Pharmaceutics"},{"key":"4185_CR178","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.bioactmat.2022.09.012","volume":"21","author":"H Wang","year":"2023","unstructured":"Wang H, Liu H, Li J, Liu C, Chen H, Li J, et al. Cytokine nanosponges suppressing overactive macrophages and dampening systematic cytokine storm for the treatment of hemophagocytic lymphohistiocytosis. Bioact Mater. 2023;21:531\u201346. https:\/\/doi.org\/10.1016\/j.bioactmat.2022.09.012.","journal-title":"Bioact Mater"},{"key":"4185_CR179","doi-asserted-by":"publisher","first-page":"1147991","DOI":"10.3389\/fimmu.2023.1147991","volume":"14","author":"A Zieli\u0144ska","year":"2023","unstructured":"Zieli\u0144ska A, Eder P, Karczewski J, Szalata M, Hryhorowicz S, Wielgus K, et al. Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: a review. Front Immunol. 2023;14:1147991. https:\/\/doi.org\/10.3389\/fimmu.2023.1147991.","journal-title":"Front Immunol"},{"key":"4185_CR180","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.683935","author":"F-D Zhu","year":"2021","unstructured":"Zhu F-D, Hu Y-J, Yu L, Zhou X-G, Wu J-M, Tang Y, et al. Nanoparticles: a hope for the treatment of inflammation in CNS. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.683935.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4185_CR181","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03572-y","volume":"23","author":"S Yuan","year":"2025","unstructured":"Yuan S, Hu D, Gao D, Butch CJ, Wang Y, Zheng H, et al. Recent advances of engineering cell membranes for nanomedicine delivery across the blood-brain barrier. J Nanobiotechnol. 2025;23(1):493. https:\/\/doi.org\/10.1186\/s12951-025-03572-y.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"4185_CR182","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12951-025-03247-8","volume":"23","author":"J Liu","year":"2025","unstructured":"Liu J, Wang T, Dong J, Lu Y. The blood\u2013brain barriers: novel nanocarriers for central nervous system diseases. J Nanobiotechnology. 2025;23(1):146. https:\/\/doi.org\/10.1186\/s12951-025-03247-8.","journal-title":"J Nanobiotechnology"},{"key":"4185_CR183","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.2147\/ijn.S442520","volume":"19","author":"P Mohapatra","year":"2024","unstructured":"Mohapatra P, Gopikrishnan M, Doss CG, Chandrasekaran N. How precise are nanomedicines in overcoming the blood-brain barrier? A comprehensive review of the literature. Int J Nanomedicine. 2024;19:2441\u201367. https:\/\/doi.org\/10.2147\/ijn.S442520.","journal-title":"Int J Nanomedicine"},{"key":"4185_CR184","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17030281","author":"A Jim\u00e9nez","year":"2025","unstructured":"Jim\u00e9nez A, Estudillo E, Guzm\u00e1n-Ruiz MA, Herrera-Mundo N, Victoria-Acosta G, Cort\u00e9s-Malag\u00f3n EM, et al. Nanotechnology to overcome blood-brain barrier permeability and damage in neurodegenerative diseases. Pharmaceutics. 2025. https:\/\/doi.org\/10.3390\/pharmaceutics17030281.","journal-title":"Pharmaceutics"},{"issue":"1","key":"4185_CR185","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1021\/acs.nanolett.9b04216","volume":"20","author":"L Xiao","year":"2020","unstructured":"Xiao L, Wei F, Zhou Y, Anderson GJ, Frazer DM, Lim YC, et al. Dihydrolipoic acid-gold nanoclusters regulate microglial polarization and have the potential to alter neurogenesis. Nano Lett. 2020;20(1):478\u201395. https:\/\/doi.org\/10.1021\/acs.nanolett.9b04216.","journal-title":"Nano Lett"},{"issue":"1","key":"4185_CR186","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s41232-024-00358-x","volume":"44","author":"SH Zhang","year":"2024","unstructured":"Zhang SH, Peng LL, Chen YF, Xu Y, Moradi V. Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy. Inflamm Regen. 2024;44(1):45. https:\/\/doi.org\/10.1186\/s41232-024-00358-x.","journal-title":"Inflamm Regen"},{"issue":"1","key":"4185_CR187","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1038\/s41467-019-12321-3","volume":"10","author":"W Fu","year":"2019","unstructured":"Fu W, Lei C, Liu S, Cui Y, Wang C, Qian K, et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun. 2019;10(1):4355. https:\/\/doi.org\/10.1038\/s41467-019-12321-3.","journal-title":"Nat Commun"},{"key":"4185_CR188","doi-asserted-by":"publisher","DOI":"10.3390\/cells11050790","author":"V Calvo","year":"2022","unstructured":"Calvo V, Izquierdo M. T lymphocyte and CAR-T cell-derived extracellular vesicles and their applications in cancer therapy. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11050790.","journal-title":"Cells"},{"key":"4185_CR189","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/bs.mcb.2021.06.017","volume":"167","author":"C Wang","year":"2022","unstructured":"Wang C, Fu W, Lei C, Hu S. Generation and functional characterization of CAR exosomes. Methods Cell Biol. 2022;167:123\u201331. https:\/\/doi.org\/10.1016\/bs.mcb.2021.06.017.","journal-title":"Methods Cell Biol"},{"key":"4185_CR190","first-page":"123","volume-title":"Methods in Cell Biology","author":"C Wang","year":"2022","unstructured":"Wang C, Fu W, Lei C, Hu S. Chapter 7 Generation and functional characterization of CAR exosomes. In: Spada S, Galluzzi L, editors. Methods in Cell Biology, vol. 167. Academic Press; 2022. p. 123\u201331."},{"issue":"8_Supplement_1","key":"4185_CR191","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1158\/1538-7445.Am2025-585","volume":"85","author":"S Qureshy","year":"2025","unstructured":"Qureshy S, Gajecki L, Veach D, Lee SG, Matei I, Carter L, et al. Abstract 585: utilizing CAR T cell-derived exosomes for radiotheranostic applications. Cancer Res. 2025;85(8_Supplement_1):585. https:\/\/doi.org\/10.1158\/1538-7445.Am2025-585.","journal-title":"Cancer Res"},{"key":"4185_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104262","volume":"360","author":"P Yang","year":"2021","unstructured":"Yang P, Cao X, Cai H, Feng P, Chen X, Zhu Y, et al. The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth. Cell Immunol. 2021;360:104262. https:\/\/doi.org\/10.1016\/j.cellimm.2020.104262.","journal-title":"Cell Immunol"},{"issue":"12","key":"4185_CR193","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1182\/bloodadvances.2024014860","volume":"9","author":"P Lanuti","year":"2025","unstructured":"Lanuti P, Guardalupi F, Corradi G, Florio R, Brocco D, Veschi S, et al. CD19.CAR T-cell\u2013derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy. Blood Adv. 2025;9(12):2907\u201319. https:\/\/doi.org\/10.1182\/bloodadvances.2024014860.","journal-title":"Blood Adv"},{"key":"4185_CR194","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101147","volume":"62","author":"JS Wang","year":"2025","unstructured":"Wang JS, Schellenberg SJ, Demeros A, Lin AY. Exosomes in review: a new frontier in CAR-T cell therapies. Neoplasia. 2025;62:101147. https:\/\/doi.org\/10.1016\/j.neo.2025.101147.","journal-title":"Neoplasia"},{"key":"4185_CR195","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jconrel.2020.07.033","volume":"326","author":"Q Xu","year":"2020","unstructured":"Xu Q, Zhang Z, Zhao L, Qin Y, Cai H, Geng Z, et al. Tropism-facilitated delivery of CRISPR\/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies. J Control Release. 2020;326:455\u201367. https:\/\/doi.org\/10.1016\/j.jconrel.2020.07.033.","journal-title":"J Control Release"},{"issue":"1","key":"4185_CR196","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s12967-023-04206-3","volume":"21","author":"W Zheng","year":"2023","unstructured":"Zheng W, Zhu T, Tang L, Li Z, Jiang G, Huang X. Inhalable CAR-T cell-derived exosomes as paclitaxel carriers for treating lung cancer. J Transl Med. 2023;21(1):383. https:\/\/doi.org\/10.1186\/s12967-023-04206-3.","journal-title":"J Transl Med"},{"issue":"17","key":"4185_CR197","doi-asserted-by":"publisher","first-page":"16770","DOI":"10.1021\/acsnano.3c03456","volume":"17","author":"T Zhu","year":"2023","unstructured":"Zhu T, Chen Z, Jiang G, Huang X. Sequential targeting hybrid nanovesicles composed of chimeric antigen receptor T-cell-derived exosomes and liposomes for enhanced cancer immunochemotherapy. ACS Nano. 2023;17(17):16770\u201386. https:\/\/doi.org\/10.1021\/acsnano.3c03456.","journal-title":"ACS Nano"},{"issue":"4","key":"4185_CR198","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3390\/cancers15041052","volume":"15","author":"S Pagotto","year":"2023","unstructured":"Pagotto S, Simeone P, Brocco D, Catitti G, De Bellis D, Vespa S, et al. CAR-T-derived extracellular vesicles: a promising development of CAR-T anti-tumor therapy. Cancers. 2023;15(4):1052.","journal-title":"Cancers"},{"issue":"1","key":"4185_CR199","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13287-024-03783-4","volume":"15","author":"F Sani","year":"2024","unstructured":"Sani F, Shojaei S, Tabatabaei SA, Khorraminejad-Shirazi M, Latifi M, Sani M, et al. CAR-T cell-derived exosomes: a new perspective for cancer therapy. Stem Cell Res Ther. 2024;15(1):174. https:\/\/doi.org\/10.1186\/s13287-024-03783-4.","journal-title":"Stem Cell Res Ther"},{"key":"4185_CR200","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105266","author":"TA Bui","year":"2024","unstructured":"Bui TA, Mei H, Sang R, Ortega DG, Deng W. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. EBioMedicine. 2024. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105266.","journal-title":"EBioMedicine"},{"issue":"8","key":"4185_CR201","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reiman D, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017;12(8):813\u201320. https:\/\/doi.org\/10.1038\/nnano.2017.57.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"4185_CR202","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","volume":"11","author":"NN Parayath","year":"2020","unstructured":"Parayath NN, Stephan SB, Koehne AL, Nelson PS, Stephan MT. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun. 2020;11(1):6080. https:\/\/doi.org\/10.1038\/s41467-020-19486-2.","journal-title":"Nat Commun"},{"key":"4185_CR203","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","volume":"350","author":"JE Zhou","year":"2022","unstructured":"Zhou JE, Sun L, Jia Y, Wang Z, Luo T, Tan J, et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. J Control Release. 2022;350:298\u2013307. https:\/\/doi.org\/10.1016\/j.jconrel.2022.08.033.","journal-title":"J Control Release"},{"issue":"11","key":"4185_CR204","doi-asserted-by":"publisher","first-page":"2304378","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley MM, Gong N, Mukalel AJ, Thatte AS, El-Mayta R, Patel SK, et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small. 2024;20(11):2304378. https:\/\/doi.org\/10.1002\/smll.202304378.","journal-title":"Small"},{"key":"4185_CR205","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010787","author":"ED Namiot","year":"2023","unstructured":"Namiot ED, Sokolov AV, Chubarev VN, Tarasov VV, Schi\u00f6th HB. Nanoparticles in clinical trials: analysis of clinical trials, FDA approvals and use for COVID-19 vaccines. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24010787.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4185_CR206","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s11033-025-10674-1","volume":"52","author":"T Saha","year":"2025","unstructured":"Saha T, Saha RP, Singh MK, Priya K, Singh S, Rajeev M, et al. An overview on in-vivo generation of CAR-T cells using CRISPR-loaded functionalized nanocarriers for treating B-cell lineage acute lymphoblastic leukemia. Mol Biol Rep. 2025;52(1):596. https:\/\/doi.org\/10.1007\/s11033-025-10674-1.","journal-title":"Mol Biol Rep"},{"issue":"43","key":"4185_CR207","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ady5579","volume":"11","author":"X Lu","year":"2025","unstructured":"Lu X, Zhu Y, Wei C, Cheng L, Goodier KD, Kong J, et al. A multistep platform identifies spleen-tropic lipid nanoparticles for in vivo T cell\u2013targeted delivery of gene-editing proteins. Sci Adv. 2025;11(43):eady5579. https:\/\/doi.org\/10.1126\/sciadv.ady5579.","journal-title":"Sci Adv"},{"issue":"Supplement 1","key":"4185_CR208","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1182\/blood-2025-4318","volume":"146","author":"R Palchaudhuri","year":"2025","unstructured":"Palchaudhuri R, Monte M, Gupta M, Schiroli G, Tozzi L, Liu L, et al. In vivo RNA delivery by targeted lipid nanoparticles enable gene editing in hematopoietic stem cells and T cells. Blood. 2025;146(Supplement 1):4318. https:\/\/doi.org\/10.1182\/blood-2025-4318.","journal-title":"Blood"},{"key":"4185_CR209","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2025.104762","volume":"146","author":"AH Ismail","year":"2025","unstructured":"Ismail AH, Khormi MA, Mawkili W, Albaqami A, Areshi S, Aborasain AM, et al. Harnessing the potential of gene-editing technology to overcome the current bottlenecks of CAR-T cell therapy in T-cell malignancies. Exp Hematol. 2025;146:104762. https:\/\/doi.org\/10.1016\/j.exphem.2025.104762.","journal-title":"Exp Hematol"},{"issue":"16_suppl","key":"4185_CR210","doi-asserted-by":"publisher","first-page":"TPS2676","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2676","volume":"42","author":"SK Pal","year":"2024","unstructured":"Pal SK, Reimers MA, Garmezy B, Xu W, Hoimes CJ, Weinstein M, et al. A phase 1\/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9\u2013engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors. J Clin Oncol. 2024;42(16_suppl):TPS2676. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS2676.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4185_CR211","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01998-8","volume":"9","author":"D Mougiakakos","year":"2024","unstructured":"Mougiakakos D. Allogeneic CAR T cells for autoimmune diseases: a glimpse into the future. Signal Transduct Target Ther. 2024;9(1):276. https:\/\/doi.org\/10.1038\/s41392-024-01998-8.","journal-title":"Signal Transduct Target Ther"},{"key":"4185_CR212","unstructured":"Centre PMC. CAR-T Cell Therapy in RelApsed\/\u200bRefractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study (CARAMEL): ClinicalTrials.gov; 2022 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT05666700."},{"key":"4185_CR213","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2020.613252","volume":"2","author":"G Blattner","year":"2020","unstructured":"Blattner G, Cavazza A, Thrasher AJ, Turchiano G. Gene editing and genotoxicity: targeting the off-targets. Front Genome Ed. 2020;2:613252. https:\/\/doi.org\/10.3389\/fgeed.2020.613252.","journal-title":"Front Genome Ed"},{"issue":"6","key":"4185_CR214","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41587-023-01915-4","volume":"42","author":"M Fiumara","year":"2024","unstructured":"Fiumara M, Ferrari S, Omer-Javed A, Beretta S, Albano L, Canarutto D, et al. Genotoxic effects of base and prime editing in human hematopoietic stem cells. Nat Biotechnol. 2024;42(6):877\u201391. https:\/\/doi.org\/10.1038\/s41587-023-01915-4.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"4185_CR215","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/s42003-025-08275-6","volume":"8","author":"W Du","year":"2025","unstructured":"Du W, Zhao L, Diao K, Zheng Y, Yang Q, Zhu Z, et al. A versatile CRISPR\/Cas9 system off-target prediction tool using language model. Commun Biol. 2025;8(1):882. https:\/\/doi.org\/10.1038\/s42003-025-08275-6.","journal-title":"Commun Biol"},{"issue":"1","key":"4185_CR216","doi-asserted-by":"publisher","first-page":"11652","DOI":"10.1038\/s41598-023-38397-y","volume":"13","author":"Y Higashitani","year":"2023","unstructured":"Higashitani Y, Horie K. Long-read sequence analysis of MMEJ-mediated CRISPR genome editing reveals complex on-target vector insertions that may escape standard PCR-based quality control. Sci Rep. 2023;13(1):11652. https:\/\/doi.org\/10.1038\/s41598-023-38397-y.","journal-title":"Sci Rep"},{"key":"4185_CR217","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12101148","author":"J Wang","year":"2024","unstructured":"Wang J, Ding Y, Chong K, Cui M, Cao Z, Tang C, et al. Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery. Vaccines. 2024. https:\/\/doi.org\/10.3390\/vaccines12101148.","journal-title":"Vaccines"},{"key":"4185_CR218","doi-asserted-by":"publisher","DOI":"10.1101\/2025.03.03.25322827","author":"VS LeBleu","year":"2025","unstructured":"LeBleu VS, Smaglo BG, Mahadevan KK, Kirtley ML, McAndrews KM, Mendt M, et al. KRAS (G12D) -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients. medRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.03.03.25322827.","journal-title":"medRxiv"},{"issue":"4","key":"4185_CR219","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS633","volume":"40","author":"R Surana","year":"2022","unstructured":"Surana R, LeBleu VS, Lee JJ, Smaglo BG, Zhao D, Lee MS, et al. Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRASG12DsiRNA in patients with metastatic pancreatic cancer harboring a KRASG12D mutation. J Clin Oncol. 2022;40(4):633.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4185_CR220","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4103\/tcmj.tcmj_182_19","volume":"32","author":"YS Chen","year":"2020","unstructured":"Chen YS, Lin EY, Chiou TW, Harn HJ. Exosomes in clinical trial and their production in compliance with good manufacturing practice. Tzu Chi Med J. 2020;32(2):113\u201320. https:\/\/doi.org\/10.4103\/tcmj.tcmj_182_19.","journal-title":"Tzu Chi Med J"},{"issue":"12","key":"4185_CR221","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","volume":"38","author":"T Lei","year":"2024","unstructured":"Lei T, Wang Y, Zhang Y, Yang Y, Cao J, Huang J, et al. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy. Leukemia. 2024;38(12):2517\u201343. https:\/\/doi.org\/10.1038\/s41375-024-02444-y.","journal-title":"Leukemia"},{"issue":"22","key":"4185_CR222","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1182\/blood.2022018924","volume":"141","author":"A Odak","year":"2023","unstructured":"Odak A, Yuan H, Feucht J, Cantu VA, Mansilla-Soto J, Kogel F, et al. Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering. Blood. 2023;141(22):2698\u2013712. https:\/\/doi.org\/10.1182\/blood.2022018924.","journal-title":"Blood"},{"key":"4185_CR223","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101123","volume":"31","author":"R Woodruff","year":"2023","unstructured":"Woodruff R, Parekh F, Lamb K, Mekkaoui L, Allen C, Smetanova K, et al. Large-scale manufacturing of base-edited chimeric antigen receptor T\u00a0cells. Mol Ther Methods Clin Dev. 2023;31:101123. https:\/\/doi.org\/10.1016\/j.omtm.2023.101123.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10","key":"4185_CR224","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nnano.2012.168","volume":"7","author":"PM Valencia","year":"2012","unstructured":"Valencia PM, Farokhzad OC, Karnik R, Langer R. Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat Nanotechnol. 2012;7(10):623\u20139. https:\/\/doi.org\/10.1038\/nnano.2012.168.","journal-title":"Nat Nanotechnol"},{"key":"4185_CR225","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.821094","volume":"9","author":"ME Reis","year":"2022","unstructured":"Reis ME, Bettencourt A, Ribeiro HM. The regulatory challenges of innovative customized combination products. Front Med. 2022;9:821094. https:\/\/doi.org\/10.3389\/fmed.2022.821094.","journal-title":"Front Med"},{"issue":"3","key":"4185_CR226","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s13346-021-01024-2","volume":"12","author":"S \u0110or\u0111evi\u0107","year":"2022","unstructured":"\u0110or\u0111evi\u0107 S, Gonzalez MM, Conejos-S\u00e1nchez I, Carreira B, Pozzi S, Ac\u00farcio RC, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2022;12(3):500\u201325. https:\/\/doi.org\/10.1007\/s13346-021-01024-2.","journal-title":"Drug Deliv Transl Res"},{"issue":"9","key":"4185_CR227","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/2326-6066.Cir-24-0482","volume":"12","author":"JK Jadlowsky","year":"2024","unstructured":"Jadlowsky JK, Chang JF, Spencer DH, Warrington JM, Levine BL, June CH, et al. Regulatory considerations for genome-edited T-cell therapies. Cancer Immunol Res. 2024;12(9):1132\u20135. https:\/\/doi.org\/10.1158\/2326-6066.Cir-24-0482.","journal-title":"Cancer Immunol Res"},{"key":"4185_CR228","unstructured":"Administration USFaD. Long Term Follow-Up After Administration of Human Gene Therapy Products: U.S. Food and Drug Administration. 2020 [Available from: https:\/\/www.fda.gov\/media\/113768\/download."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04185-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04185-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04185-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:32:33Z","timestamp":1779204753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04185-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":228,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4185"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04185-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Dual publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to use third-party material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}